Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service sinus surgery & balloon dilation cases in New Hampshire: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (231 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 258 | 21% |
| 2020 | 0 | 158 | 25% |
| 2021 | 1 | 230 | 29% |
Balloon sinuplasty and functional endoscopic sinus surgery. Professional codes (what the surgeon bills): CPT 31295, 31296, 31297, 31298, 31255, 31267, 31276, 31287, 31288, 31237.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Hampshire; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 61 | 6,979−3.8%/yr | −3.8%/yr | 3.9 | 89% | 7,410 in 2030+1%/yr |
| Pennsylvania | 51 |
Sinus surgery & balloon dilation in every state, and its device makers · Every procedure market in New Hampshire · Every state · Compare with New York
| 2024 |
| 250 |
| 39% |
| 2025 est. | ≈ 260 | – |
| 2026 est. | ≈ 290 | – |
| 2022 | 1 | 220 | 33% |
| 2023 | 1 | 235 | 37% |
| 2024 | 1 | 250 | 39% |
| 2025 from claims | – | 257 208–302 | 40% |
| 2026 forecast | – | 288 226–362 | 35% |
| 2027 forecast | – | 300 223–397 | 34% |
| 2028 forecast | – | 312 221–431 | 34% |
| 2029 forecast | – | 325 221–466 | 33% |
| 2030 forecast | – | 338 222–502 | 33% |
In 2025, 55% hospital outpatient, 45% office. The share outside the hospital has moved −14 pts since 2019.
| 5,134−4.5%/yr |
| −4.5%/yr |
| 3.8 |
| 58% |
| 5,170 in 2030+0.1%/yr |
| New Jersey | 22 | 3,263+0.4%/yr | +0.4%/yr | 3.1 | 94% | 4,190 in 2030+4.2%/yr |
| Massachusetts | 25 | 2,622−3.9%/yr | −3.9%/yr | 2.8 | 53% | 3,080 in 2030+2.7%/yr |
| Connecticut | 10 | 1,256−2.8%/yr | −2.8%/yr | 3.8 | 97% | 1,730 in 2030+5.5%/yr |
| Maine | 4 | 254−3.5%/yr | −3.5%/yr | 1.6 | 0% | 510 in 2030+12%/yr |
| Rhode Island | 0 | 108−12%/yr | −12%/yr | 1.2 | 59% | 90 in 2030−3.1%/yr |
No metro breakdown yet.
Stryker leads with 100% of company spending on these surgeons in 2025, +86 pts on 2024.
In 2025, 1 company reported engagement with New Hampshire’s surgeons worth $32 in consulting, speaking, meals and travel tied to these products, about $32 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.